Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C32H41N3O4 and a molecular weight of approximately 531.7 g/mol. It is classified as an experimental drug and has not been approved for any therapeutic use in the United States or elsewhere. The structure features a benzamide core substituted with various functional groups including an aminophenol moiety and a dimethylphenoxy-acetate side chain. There are no reported clinical trials or indications for this compound as of now. Its mechanism of action has not been described in public databases; it appears to be primarily used in research contexts rather than clinical development[7][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-Amino-N-{4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide.